A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial

Authors:

Abstract
No abstract available
Funding Information
  • F. Hoffmann-La Roche

This publication has 40 references indexed in Scilit: